Floatz logo

LAROPIPRANT

Metabolic Syndrome

Ludwig-Maximilians - University of MunichSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
73/ 100

Competitive context

44 Active assets in the Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Lipitor
Seoul National University Hospital
Phase 4BBB
Topamax
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Rosuvastatin
Dr. B. Catharine. Craven
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
SIMVASTATIN
Jaime Daniel Mondragon
Phase 4BBB

View all 50 →

Same molecule, other indications

LAROPIPRANT is also rated in:

hyperlipoproteinemiaDormant
B
Indicative ·
63 / 100
View asset →
coronary artery disorderDormant
B
Indicative ·
62 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →